Systematic Review

Effects of Ketamine on Chronic Postsurgical Pain in Patients Undergoing Surgery: A Systematic **Review and Meta-analysis**

Wanchen Sun, MD, Yang Zhou, MD, Juan Wang, MD, Yuxuan Fu, MD, Jingyi Fan, MD, Yidan Cui, MD, Yishuang Wu, MD, Lianjie Wang, MD, Yun Yu, MD, and Ruguan Han, MD, PhD From: Beijing Tiantan Hospital, Background: Chronic postsurgical pain (CPSP) has become a common complication during the Capital Medical University, perioperative period. The efficacy of one of the most potent strategies, ketamine, remains unclear. People's Republic of China Objectives: The aim of this meta-analysis was to evaluate the effect of ketamine on CPSP in Address Correspondence: patients undergoing common surgeries.. Ruquan Han, MD, PhD Beijing Tiantan Hospital Capital Medical University Study Design: Systematic review and meta-analysis. People's Republic of China E-mail: ruquan.han@ccmu.edu.cn Methods: English-language randomized controlled trials (RCTs) published in MEDLINE, Cochrane Library, and EMBASE from 1990 through 2022 were screened. RCTs with a placebo control group Disclaimer: Wanchen Sun and that evaluated the effect of intravenous ketamine on CPSP in patients undergoing common surgeries Yang Zhou contributed equally were included. The primary outcome was the proportion of patients who experienced CPSP 3 - 6 to this work. This study was months postsurgery. The secondary outcomes included adverse events, emotional evaluation, and 48 supported was supported by Clinical Medicine Development hour postoperative opioid consumption. We followed the Preferred Reporting Items for Systematic of Special Funding Support Reviews and Meta-analyses (PRISMA) guidelines. Pooled effect sizes were measured using the (ZYLX201708; DFL20180502) and common-effects model or random-effects model, and several subgroup analyses were conducted. the Beijing Municipal Science & Technology Commission (No. Ž191100006619067). Results: Twenty RCTs were included with 1,561 patients. Our pooled meta-analysis showed a significant difference between ketamine and placebo in the treatment of CPSP (Relative Risk [RR] = Conflict of interest: Each author 0.86; 95% CI, 0.77 – 0.95; P = 0.02; $I^2 = 44\%$). In the subgroup analyses, our results indicated that certifies that he or she, or a compared with placebo, intravenous ketamine might decrease the prevalence of CPSP 3 – 6 months member of his or her immediate postsurgery (RR = 0.82; 95% CI, 0.72 - 0.94; P = 0.03; $l^2 = 45\%$). For adverse events, we observed family, has no commercial association (i.e., consultancies, that intravenous ketamine might lead to hallucinations (RR = 1.61; 95% CI, 1.09 - 2.39; P = 0.27; I² stock ownership, equity interest, = 20%) but did not increase the incidence of postoperative nausea and vomiting (RR = 0.98; 95% patent/licensing arrangements, Cl, 0.86 – 1.12; *P* = 0.66; l² = 0%). etc.) that might pose a conflict of interest in connection with the submitted manuscript. Limitations: Inconsistent assessment tools and follow-up for chronic pain may contribute to the high heterogeneity and limitation of this analysis. Manuscript received: 10-29-2022 Revised manuscript received: Conclusions: We discovered that intravenous ketamine may reduce the incidence of CPSP in 12-27-2022 Accepted for publication: patients undergoing surgery, especially 3 - 6 months postsurgery. Because of the small sample size 01-04-2023 and high heterogeneity of the included studies, the effect of ketamine in the treatment of CPSP still needs to be explored in future large-sample, standardized-assessment studies. Free full manuscript: www.painphysicianjournal.com Key words: Ketamine, chronic postsurgical pain, perioperative period, meta-analysis, randomized controlled trial Pain Physician 2023: 26:E111-E122 hronic postsurgical pain (CPSP), an important time after surgery, usually for more than 3 months (1). complication following surgery, is defined

as pain that persists past the normal healing

According to previous research, the prevalence of CPSP is 10% - 50% across all surgeries (2). Once a patient develops CPSP, many other complications can emerge. Experiencing CPSP might impair cognitive function (3) and may increase the risk of senile dementia in elderly patients (4). Persistent pain can also influence the emotional and mental health of the patient, which could in turn yield an unfavorable prognosis for the patient (5,6). However, no effective treatment for CPSP has yet been found.

The mechanism underlying the development of CPSP is believed to be closely related to the release of inflammatory factors due to injury at the surgical site and nearby nerves, which are thought to mediate peripheral and central sensitization (7). N-methyl-D-aspartate (NMDA) receptors notably seem to play a critical role in the development of CPSP (8). Consequently, ketamine and one of its enantiomers, S-ketamine, as an NMDA receptor antagonist, have taken on a competitive role in the treatment of CPSP. The effect of perioperative intravenous ketamine/S-ketamine on acute postsurgical pain (APSP) has been confirmed in many previous studies (9,10). Nevertheless, in the past few years, few studies have focused on the preventive efficacy of ketamine on CPSP.

In 2013, a meta-analysis suggested that ketamine could decrease the risk of CPSP at 3 months postoperatively (11). One year later, another meta-analysis emphasized that intravenous ketamine, rather than epidural ketamine, might prevent the occurrence of CPSP (12). However, because of the small sample sizes, limited number, and high heterogeneity of the included studies, the conclusion was unreliable. In 2020, an updated, large-scale meta-analysis including 110 studies performed 15 meta-analyses on the role of ketamine but returned a negative conclusion (13). Because of the various regimens for administering ketamine and the different assessment methods, the results could only suggest a general impression, especially regarding whether intravenous ketamine could play a role in preventing CPSP.

Thus, the objective of our systematic review and meta-analysis was to examine the efficacy of intravenous ketamine/S-ketamine in the treatment of CPSP in patients undergoing common surgeries and to observe the influence of different interventional regimens on preventing CPSP. These findings may provide new ideas for preventing CPSP to help improve the quality of life of patients undergoing surgery.

METHODS

This systematic review and meta-analysis was

conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol of the systematic review was registered with PROSPERO (CRD42021227332) and published elsewhere.

Search Strategy and Data Source

We selected relevant studies published from 1990 through 2022 by searching Embase, MEDLINE (PubMed), and the Cochrane Library. We used the following combined text and MeSH terms as search words: ("Ketamine"[MeSH] OR "ketamine hydrochloride" OR "NMDA Receptor antagonist") AND (("Pain, Postoperative"[MeSH] OR "Chronic Pain"[MeSH] OR "Neuralgia"[MeSH] OR ("operation" OR "surgery")). The search results were limited to randomized controlled trials (RCTs). The details of the entire search strategy are in the eMethods Supplement.

Eligibility Criteria


We selected RCTs in accordance with the following inclusion criteria: 1) patients from any surgical population undergoing general anesthesia; 2) intravenous administration of a bolus and/or continuous infusion, or via a patient-controlled analgesia device of ketamine/S-ketamine during the perioperative period with no restrictions of dosage and duration; 3) a placebo-control group in RCTs; and 4) the proportion of patients with CPSP 3 – 6 months postoperatively as one of the study outcomes, evaluated by any relative scale. Studies on animals, reviews, and case reports were excluded. We also excluded papers not reported in the English language.

Study Selection

Two independent reviewers (W.S. and Y.Z.) screened the study titles and abstracts to identify potential articles. Subsequently, 2 reviewers (W.S. and Y.Z.) read the articles thoroughly to make a final decision. Both reviewers independently determined whether to include the study. In cases of conflicts, a third researcher (J.W.) was involved in the discussion. The process and details of study selection are shown in Fig. 1.

Data Extraction

Reference data, populations, and outcomes were extracted from the articles into a prespecified table form by 2 authors (W.S. and Y.Z.) independently. Original information included the studies' general characteristics (first author's last name, publication year, etc.),



patients (demographic characteristics, sample size, type of surgery, etc.), intervention (dosage and duration of experimental drug administration, groups, etc.), and outcomes (prevalence of CPSP, assessment tools, time points of follow-up, adverse events, opioid consumption, etc.). The researchers attempted to contact the authors of these studies when they needed more information about their analyses or reported results.

Study Quality Assessment

Study quality was assessed by 2 independent researchers (W.S. and J.W.) Based on the Cochrane Collaboration's Risk of Bias (RoB) one tool, the following 7 key domains were examined: adequate random sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcomes, incomplete outcome data, selective outcome reporting, and other biases.

The Jadad scale was used to assess the methodological quality of the selected RCTs. We defined RCTs with a score between 4 and 5 points as medium quality; those with a score between 6 and 7 were regarded as high-quality studies.

Outcome Measures and Data Synthesis

The diagnostic criteria for CPSP could depend on

any relative assessment scale, such as the Visual Analog Scale (VAS), Numeric Rating Scales (NRS-11), Douleur Neuropathique 4 questionnaire (DN4), or even selfdesigned scales.

The number of patients with CPSP in the 2 groups at each time point was extracted, as well as the total number of patients in each group. The primary outcome was the proportion of patients undergoing surgery who experienced CPSP in the ketamine/S-ketamine group and control group 3 – 6 months postoperatively. The secondary outcomes included total opioid consumption within 48 hours postoperatively; the incidence of adverse events, including postoperative nausea and vomiting (PONV) and hallucinations; and the prevalence of depression and anxiety postoperatively. The included counting data are presented as relative risks (RRs) with 95% Cls, and the continuous data are presented as the mean differences (MD) with 95% Cls.

Statistical Analysis

The primary outcome was assessed with R version 4.1.3 with the meta package, version 5.2.0 (The R Foundation). Quantitative pooling analyses for the prevalence of CPSP were performed with the Mantel-Haenszel fixed-effects model, and trial weights were estimated by the inverse variance method. The effects of ketamine on CPSP prognostic outcomes were assessed by pooled RRs for dichotomous variables and MDs for continuous variables, and the 95% Cls were estimated. Statistical heterogeneity in this meta-analysis was assessed by using the l² statistic. A random-effects model was used for pooled analyses with significant heterogeneity (l² \ge 50%), and the fixed-effects (common effects) model was only used for analyses with moderate or low heterogeneity (l² < 50%).

For the primary outcome, predefined subgroup analyses were conducted to detect the influence of certain trial design factors on heterogeneity between the included studies. Subgroups included type of surgery, CPSP assessment methods, length of follow-up for CPSP, and duration or dosage of ketamine infusion. Sensitivity analysis was performed by iteratively omitting each study from the pooled results. For publication bias analysis, a funnel plot and Egger's test were performed to assess the effects of small studies. A contourenhanced funnel plot was inspected for asymmetry, and 2-sided P values < 0.05 for Egger's test indicated statistical significance.

Trial sequential analysis (TSA) was performed to determine whether the current sample size reached the threshold for statistical significance with TSA Version 0.9.5.10 (Copenhagen Trial Unit). The primary TSA was conducted by setting α to 0.05, power to 80%; estimated diversity and variances were estimated by the included trials.

RESULTS

Literature Search

A total of 1,023 studies were identified through the initial search. We removed duplicate records and then selected relevant publications by screening abstracts and titles; the full texts of 43 studies were subsequently read. An additional 21 studies were excluded due to failure to meet the inclusion criteria, as listed in Fig. 1. Because of insufficient data available for the meta-analysis, 2 articles were excluded. Finally, 20 studies with 1,561 patients were included in the final analysis.

Study Characteristics

All included RCTs assessed the incidence of CPSP between ketamine/S-ketamine and placebo for patients undergoing any surgical procedure for 3 – 6 months postoperatively; 3 studies used S-ketamine as the interventional drug, and the others used ketamine. Among the trials, 6 enrolled patients undergoing thoracotomy (14-19); 6 included patients scheduled for orthopedic surgery: 3 reported on patients undergoing total hip/ knee arthroplasty (20-22), 2 enrolled patients undergoing spinal surgery (23,24), and one described an amputation (25); 2 included patients prior to breast surgery (26,27); and the other 6 trials included thyroidectomy (28), rectal adenocarcinoma surgery (29), hemorrhoid-ectomy (30), open nephrectomy (31), abdominal or thoracic surgery (32), and cesarean delivery (33).

Among the 1,561 patients, 58.4% were women. The age of the patients was 45.9 ± 7.9 years. The sample size of the included studies ranged from 16 to 184. Fifteen percent of the studies had a sample size of less than 50, 50% had between 50 and 100 patients, and 35% had more than 100 patients. Regarding the interventions of the included studies, 2 of the trials had 3 groups, including ketamine, placebo, and other drugs (20,31); and 2 trials included an intravenous ketamine group, epidural ketamine group, and placebo group, for which we extracted only the data of the intravenous (IV) ketamine and placebo groups (16,29). According to the different dosages and routes, one trial was designed to have 4 arms (33), and one trial had 5 arms (29).

Risk of Bias Assessment

Quality assessment of the RCTs was based on the Cochrane Collaboration's RoB 1 tool (Supplemental Figs. 10 and 11). Five studies did not describe the method of random sequence generation (15,20,22,31,32). Regarding allocation concealment, 8 trials did not mention its implementation (15-17,19,20,25,29,33), and one trial prepared study medications by number (24). For blinding, 5 trials did not indicate blinding of the patients and investigators (15,17,19,20,22), and 3 studies did not introduce assessment blinding (15,19,22). Two trials yielded bias in incomplete outcome data (32,33), and 4 trials had biases in selective outcome reporting (17,20,29,33). Based on the Jadad scale, 8 trials were of medium quality, and the others were of high quality; the details are shown in Table 1.

Primary Outcome

All 20 RCTs reported the number of patients with CPSP in the 2 groups (ketamine and placebo) 3 – 6 months postsurgery. Nine studies (14,16,17,19,26-28,30,31) evaluated CPSP 3 months postoperatively, and the other studies evaluated CPSP occurring after 3 months but within 6 months. For the assessment standard, 4 trials (20,24,26,31) used a DN4 score of \geq 4, 10

Study	Year	Type of Surgery	Sample Size	Number of Groups	Infusion Regimen	Dosage of Ketamine/S-ketamine	Duration of Ketmaine	Assessment of CPSP	Time Points of Follow-up	JADAD
Dekock	2001	Rectal surgery	86	5	EP/IV	Bolus 0.25 mg/kg + 0.125 mg/kg/h or 0.5 mg/ kg + 0.25 mg/kg/h	During surgery	self-designed	1 m, 6 m, 12 m	5
Hayes	2004	Knee amputation	45	2	IV	bolus 0.5 mg/kg + 0.15 mg/kg/h	72 h	self-designed	6 m	9
Suzuki	2006	Thoracotomy	49	2	IV	Bolus 0 mg/kg + 0.05 mg/kg/h	72 h	NRS	1 m, 3 m, 6 m	5
Duale	2009	Thoracotomy	86	2	IV	Bolus 1 mg/kg + 1 mg/kg/h (during surgery) + 1 mg/kg (post 24 h)	24 h	ISdN	1.5 m, 4 m	2
Remerand	2009	THA	154	2	IV	Bolus 0.5 mg/kg + 0.12 mg/kg/h	24 h	self-designed	1 m, 3 m, 6 m	7
Perrin	2009	TKA	16	2	IV	Bolus 0.5 mg/kg + 0.24 mg/kg/h	During surgery	SdM	6.5 m	5
Spreng	2010	Haemorrhoidectomy	77	2	IV	Bolus 0.35 mg/kg + 0.3 mg/kg/h	During surgery	NRS	3 m	2
Mendola	2012	Thoracotomy	62	2	IV	Bolus 0 mg/kg + 0.1 mg/kg/h	60 h	NRS	1 m, 3 m, 6 m	5
Bligen	2012	Cesarean delivery	140	4	IV	Bolus 0.25 mg/kg or Bolus 0.5 mg/kg or Bolus 1 mg/kg	Only bolus	Self-designed	1 m, 6 m, 12 m	5
Hu	2014	Thoracotomy	78	2	IV	Bolus 1 mg/kg + 0.12 mg/kg/h	72 h	NRS	2 m, 6 m	4
Tena	2014	Thoracotomy	104	3	EP/IV	Bolus 0.5 mg/kg + 0.25 mg/kg/h	48 h	VAS	3 m, 6 m	9
Aveline	2014	TKA	69	3	IV	Bolus 0.2 mL/kg + 0.12 mg/kg/h (during surgery) + 0.06 mg/kg/h (post 48 h)	48 h	DN4	6 m, 12 m	4
Nielsen	2017	Lumbar spinal fusion surgery	147	2	IV	Bolus 0.5 mg/kg + 0.25 mg/kg/h	During surgery	VAS	6 m, 12 m	7
Jendoubi	2017	Elective open nephrectomy	63	3	IV	Bolus 0.15 mg/kg + 0.1 mg/kg/h	24 h	DN4	3 m	9
Peyton	2017	Abdominal or thoracic surgery	80	2	IV	Bolus 0.5 mg/kg + 0.25 mg/kg/h (during surgery) + 0.1 mg/kg/h (post 24 h)	24 h	NRS	6 m	6
Lee	2018	Thyroidectomy	64	2	IV	Bolus 0.15 mg/kg + 0.12 mg/kg/h	During surgery	NRS	3 m	7
Chumbley	2019	Thoracotomy	70	2	IV	Bolus 0.1 mg/kg + 0.1 mg/kg/h	96 h	NPS	1 m, 3 m, 6 m, 12 m	4
Kang	2020	Breast cancer surgery	184	2	IV	Bolus 0.5 mg/kg + 0.12 mg/kg/h	During surgery	NRS	1 m, 3 m, 6 m	2
Czarnetzki	2020	Lower back surgery	160	2	IV	Bolus 0.25 mg/kg + 0.25 mg/kg/h (during surgery) +0.1 mg/kg/h (PACU)	During surgery	DN4	6 m, 12 m	5
Zhao	2021	Modied radial mastectomy	100	2	IV	Bolus 0.5 mg/kg + 0.25 mg/kg/h	During surgery	DN4	3 m	7

www.painphysicianjournal.com

trials (14-17, 19, 23, 27, 28, 30, 32) used the NRS-11, VAS, or Numeric Pain Scores (NPS) to evaluate pain intensity, 4 trials (21, 25, 29, 33) had self-designed scales, one trial (18) used the Neuropathic Pain Symptoms Inventory (NPSI) scale, and one trial (22) assessed CPSP with the Womac pain subscale.

In the analysis of these 20 RCTs with 1,561 patients, the pooled results indicate that 3 - 6 months postoperatively, compared with placebo, IV ketamine might decrease the incidence of CPSP (RR = 0.86; 95% CI, 0.77 - 0.95; P = 0.02; $I^2 = 44\%$, Fig. 2). The funnel plot is presented in Fig. 3, showing that publication bias was not observed in any study. Egger's test also showed no publication bias (P = 0.66).

Secondary Outcomes

Adverse Events

Fourteen of the 20 trials reported the incidence of adverse events during the postoperative period. Meta-analysis of the data revealed that compared with placebo, IV ketamine did not increase the incidence of PONV (RR = 0.98; 95% CI, 0.86 – 1.12; P = 0.66; $I^2 =$ 0%) (Supplemental Fig. 1). However, the pooled data showed that IV ketamine might increase the risk of postoperative hallucinations (RR = 1.61; 95% CI, 1.09 – 2.39; P = 0.27; $I^2 = 20\%$) (Supplemental Fig 2). In addition, we also summarized the incidence of adverse drug reactions in the 20 included studies; details are in the Supplementary Table.


Opioid Consumption 48 Hours Postoperatively

Fourteen trials (14,15,17-19,21-25,27,31-33) observed the total postsurgery opioid consumption; 2 trials (17,19) performed postoperative analgesia via patient-controlled epidural analgesia , so their results were based on the epidural dosage. Six studies (14,18,24,25,27,32) are presented as the median (IQR). One study (15) only reported the total opioid consumption at 72 hours. Finally, only 5 studies (21-23,31,33) were included in the analysis; no difference was observed between the 2 groups in opioid consumption (Mean Difference = -7.37; 95% Cl. -20.06 to 5.33; P <0.01; $I^2 = 93\%$) (Supplemental Fig. 3).

Depression and Anxiety

Only one study (27) focused on the postsurgical emotional assessment of patients. Kang et al (27) found that the prevalence of depression was nearly 13 - 14% in patients after breast surgery from one to 6 months

tudy	Experin		Cor Events	ntrol Total	Favors intervention	Favors	RR	95%-CI	Weight (common)	Weight (random		34	5	67	78
ludy	Lvents	Total	Lvents	Iotai	intervention	control	nn	55 /6-01	(common)	liandon	,				
Dekock-2001	2	38	6	18			0.16	[0.04; 0.71]		1.0%		00			
Hayes-2004	4	15	4	16		•	1.07	[0.32; 3.52]		1.6%					
Suzuki-2006	7	22	14	22			0.50	[0.25; 1.00]		4.1%					
Duale-2009	16	34	24	35			0.69	[0.45; 1.05]		8.1%	\odot)(
Remerand-2009	6	72	21	70	I		0.28	[0.12; 0.65]		3.0%	\odot)(
Perrin-2009	3	5	2	7			2.10	[0.53; 8.29]		1.2%	\bullet				
Spreng-2010	6	39	3	38			1.95	[0.52; 7.24]		1.3%)(
Mendola-2012	11	31	8	30			1.33	[0.62; 2.84]		3.5%					
Bilgen-2012	6	115	2	35			0.91	[0.19; 4.32]		1.0%				0(
Hu-2014	18	31	24	47	+	#	1.14	[0.75; 1.71]		8.4%					
Tena-2014	9	33	17	35			0.56	[0.29; 1.08]		4.5%				\bigcirc	
Aveline-2014	2	24	6	23			0.32	[0.07; 1.42]		1.1%					29
Nielsen-2017	38	43	49	52	÷)	0.94	[0.83; 1.07]		17.1%	00				
Jendoubi-2017	7	20	9	20			0.78	[0.36; 1.68]		3.5%				QÇ	$\mathcal{O}(\mathcal{O})$
Peyton-2017	8	40	6	40	-	•	1.33	[0.51; 3.49]		2.4%				QÇ	25
Lee-2018	9	25	10	24			0.86	[0.43; 1.75]		4.0%				O (DC
Chumbley-2019	10	33	8	34		•	1.29	[0.58; 2.86]		3.3%				QÇ	25
Zhao-2021	27	42	23	44		*-	1.23	[0.86; 1.76]		9.6%				Qç	25
Kang-2020	58	84	73	84			0.79	[0.67; 0.94]		15.9%					20
Czarnetzki-2020	21	73	16	68		-#	1.22	[0.70; 2.14]	5.2%	5.6%					
Common effect m	nodel	819		742			0.86	[0.77; 0.95]	100.0%		Low	U	nclea	r C	Hi
Random effects r	nodel						0.88	[0.75; 1.03]		100.0%	_				
Heterogeneity: /2= 44%,	$t^2 = 0.0338$	$B_{\rm D} = 0.0$	02		0.1 0.5	1 2 10				Rar	ndom se		-		
notorogenengtr = 4476,	1 = 0.0000	, p = 0.	~~		0.1 0.5	1 2 10					Alloc	cation	conce	ealm	ent
									В	linding of	particip	ants ar	nd pe	rsor	inel
										Blindi	ng of ou	tcome	asse	ssm	ient
											Incom				
												Select	tive re	eport	ting
Fig 2. <i>Primary</i>	outcon	ne con	mhinea	l traffic	nlot.								Ot	her b	oias
					<i>r</i>									Ove	erall



postoperatively; there were no significant differences between the 2 groups (one month: P = 0.635; 3 months: P = 0.311; 6 months: P = 0.801). This study also evaluated anxiety within 24 hours postoperative and did not observe a difference (P = 0.682).

Subgroup Analyses and Sensitivity Analysis

For the primary outcome, the l² statistic was 44% for the meta-analysis of intravenous ketamine from 20 RCTs. These outcomes indicated the presence of a moderate degree of heterogeneity. Many factors might cause this heterogeneity, including the type of surgery, assessment method, follow-up time points, and variations in the infusion regimen and placebo. To explore the sources of heterogeneity, we conducted 4 subgroup analyses and a sensitivity analysis. No significant differences were shown in the subgroup analyses for different surgical types, including orthopedic surgery, thoracotomy, abdominal surgery, thyroid surgery, or breast surgery (Supplemental Fig. 4).

One study enrolled a mixed surgery population, including thoracotomy, abdominal surgery, and breast surgery, so this trial was analyzed in different subgroups 3 times. Moreover, the various interventional regimens were estimated. Unfortunately, we found no significant differences among the following groups: infusion rate $\leq 0.125 \text{ mg/kg/h vs} > 0.125 \text{ mg/kg/h}$; duration of intervention only during surgery; within 24 hours vs more than 24 hours; and a bolus dose of IV ketamine $\geq 0.5 \text{ mg/kg vs} < 0.5 \text{ mg/kg}$ (Supplemental Fig. 5). We also investigated the different time periods for assessing CPSP, including < 3 months, at 3 months, > 3 months, $\leq 6 \text{ months}$, > 6 months, and $\leq \text{ one year. Finally}$, we observed significant differences between > 3 and \leq 6 months (RR = 0.82; 95% CI, 0.72 to 0.94; P = 0.03; $I^2 = 45\%$) (Supplemental Fig. 6). Moreover, we evaluated the different assessment methods for CPSP; we placed similar scales in the same subgroup, including VAS/NRS-11, DN4, self-designed scale (DIY) and NPSI. The results showed that under the same or similar scales, the effect of ketamine/S-ketamine could be observed more easily (Supplemental Fig. 7).

A sensitivity analysis was performed by sequentially removing each individual trial and evaluating how its removal affected the pooled estimate of the primary outcome. The results showed that omitting the study of Zhao (26) might have little influence on the outcomes (RR = 0.85; 95% CI, 0.74 to 0.98) (Supplemental Fig. 8).

Trial Sequential Analysis (TSA)

TSA for the effect of ketamine on CPSP was inconclusive, and the cumulative z-curve did not cross the benefit, harm, or futility threshold. The current evidence was not sufficient to clarify the effect of ketamine on CPSP. (Supplemental Fig. 9)

DISCUSSION

This systematic review and meta-analysis of 20 RCTs evaluated intravenous ketamine/S-ketamine infusions versus placebo for CPSP in patients undergoing any type of surgery during the perioperative period. The results revealed that IV ketamine/S-ketamine use during the perioperative period could reduce the risk of CPSP in patients undergoing surgery. In the subgroup analysis, we found that standard assessment could help decrease the heterogeneity of the pooled results. Additionally, regarding adverse events, the incidence of hallucinations with IV ketamine/S-ketamine was higher than that with placebo, but no effect was observed on the incidence of PONV.

Because of the associated economic burden and substantial functional impairment, CPSP is becoming an important issue in the field of perioperative medicine. In a previous study (34), the average prevalence of CPSP was almost 10% in the population undergoing surgery. Additionally, more than 320 million people require surgical treatment for their disease (7).

Based on the current severe situation, researchers have been seeking better ways to prevent or treat CPSP for the past few years. It is hypothesized that the development of CPSP and central sensitization requires high-concentration bombardment and blockade of NMDA receptors, which are intimately involved in neuroplasticity. Ketamine is a traditional intravenous anesthetic that exerts its analgesic effect by antagonizing NMDA receptors. As a result, ketamine and S-ketamine, one of its enantiomers, have become some of the most competitive drugs for alleviating CPSP. In 2014, McNicol et al (12) conducted a meta-analysis and demonstrated that perioperative IV ketamine reduces the risk of developing CPSP between 3 and 6 months postsurgery. The effect of ketamine has also been confirmed for other chronic pain populations, such as those with complex regional pain syndrome (both Type 1 and Type 2) (35) or chronic pain (36).

In 2020, an updated meta-analysis showed that ketamine might not prevent CPSP well (13), which seems to contradict our conclusions. However, their inclusion criteria were different from ours: they included all ketamine infusions, not only intravenous but also epidural administration, and they also included combinations of ketamine and other drugs, which might result in a higher heterogeneity of outcome, which might explain why the effect of ketamine/S-ketamine on CPSP was not observed in their study. On the other hand, we only enrolled studies that used intravenous ketamine/S-ketamine administration, which might explain the dissimilarity.

Pain and depression are reciprocally related (37-39). CPSP might increase the risk of depressive symptoms in patients who have had surgery. Once patients with CPSP suffer from depression, their prognosis worsens, so it is vital for clinicians to identify patients who have had surgery with depressive symptoms in time. According to one study (40), a subanaesthetic infusion of ketamine/S-ketamine had an obvious effect on depression. Moreover, our research team found that subanaesthetic ketamine could effectively decrease depressive symptoms in patients undergoing neurosurgical procedures (41). The conclusions seem to suggest that appropriate doses of ketamine could effectively address pain and depression.

However, IV ketamine might cause more significant dissociative symptoms and transient cardiovascular reactions (blood pressure elevations and/or higher heart rates). These side effects might limit the use of ketamine in patients with depression during the perioperative period. Concerns include the following: 1) intraoperative administration may alter the depth of anesthesia, and patients undergoing surgery who have depression often have a decreased tolerance to anesthesia; 2) continuous postsurgery IV ketamine could cause dissociative symptoms and hallucinations in patients with depression, which might further aggravate anxiety and depression; and 3) patients with depression usually need to take antidepressants to control the disease. How to balance the effects of antidepressants on perioperative management and the control of patients' depression is a crucial challenge for anesthesiologists. Thus, the most appropriate delivery strategy of ketamine needs to be clear as soon as possible.

According to a previous study, the incidence and intensity of CPSP are different among different patients undergoing surgery (7). Therefore, we performed subgroup analyses for different surgeries; ultimately, however, the data did not show differences between the 2 groups for each type of surgery. The results are consistent with those of previous studies (12,13).

Few previous related systematic reviews and metaanalyses have focused on the dosage or duration of the ketamine infusion regimen, despite it having a substantial effect on the analgesic effect of ketamine. Based on previous opinions, poorly controlled APSP is an independent risk factor for CPSP (42) and could increase the risk of CPSP 3-fold (43). We considered that a higher dosage and longer duration might result in better control of acute postoperative pain, influencing the development of CPSP. Our subgroup analysis of the infusion regimen was divided into 3 parts: the infusion rate, the bolus dosage, and the continuous duration. A previous updated review showed that the duration of ketamine administration was not related to the risk of CPSP in 3 – 6 months, which was opposite to their previous review (13). However, our results are consistent with these new observations. In addition, we also designed a secondary outcome of 48-hour opioid consumption to

explore the relationship between APSP and CPSP, but due to the excessive heterogeneity and little accurate data, we could not find meaningful results.

Moreover, none of the previous studies observed whether different assessment tools affected the evaluation of CPSP. Therefore, we performed a subgroup analysis to examine this issue. According to our results, we found that under the same scale, we could decrease the heterogeneity and find differences between the 2 groups. In other words, a unified evaluation helped us observe the results more clearly and obtain a conclusion more easily. Therefore, it is very important for future studies to use standard evaluation methods and fixed follow-up points.

The adverse effects of intravenous ketamine/S-ketamine were also evaluated in our meta-analysis. PONV is one of the most common postoperative complications of intravenous ketamine/S-ketamine. Our pooled data indicates that there were no significant differences in the incidence of PONV between the 2 groups. The same results were reported in a meta-analysis investigating the effect of IV ketamine on early APSP (9). Moreover, we assessed the proportion of hallucinations in all of the included studies, which is a specific adverse reaction of ketamine and its enantiomer administration. Finally, we found that IV ketamine seemed to produce a greater proportion of hallucinations than placebo. According to our secondary outcomes, we also planned to investigate the proportion of depression and anxiety in these populations. Depression and anxiety are common complications of CPSP and always lead to a poor prognosis (44,45). Unfortunately, only one study reported postsurgery emotional assessment, but we still think that it is very important to explore the relationship and influence between mood and CPSP. We suggest that future studies pay more attention to this field.

Our systematic review and meta-analysis has several limitations. First, there was possible publication bias in our review because of the exclusion of non-English papers. However, in our analysis, which consisted of a funnel plot and Egger's test, we did not observe any publication bias. Second, the incidence of CPSP was not the primary outcome in all included articles, which meant that the outcome of CPSP in some enrolled studies had insufficient power, potentially reducing the reliability of the results in our meta-analysis. At the same time, the sample size of some included papers was small, which might also have increased the reporting bias. Combined with the TSA results, these limitations indicate that further large-population and high-quality research is needed. Finally, the inconsistent assessment tools for the primary outcome possibly increased the heterogeneity of the results and made additional analysis difficult. Therefore, investigators should consider using a unified method to assess the prevalence of CPSP in the future to discuss effective drugs to prevent this severe problem.

CONCLUSIONS

Perioperative IV ketamine likely reduces the incidence of CPSP in patients undergoing surgery, especially 3 – 6 months postsurgery, while increasing the occurrence of hallucinations but not PONV. However, because of the high heterogeneity of the interventional regimens and assessment methods, our confidence in this analgesic effect is limited. Moreover, we found that using a uniform scale could decrease the heterogeneity and observe the effect of ketamine on CPSP more obviously. Therefore, additional standardized assessments and large-scale studies are needed to confirm this conclusion in the future.

6.

7.

REFERENCES

- Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain 2015; 156:1003-1007.
- Chen Q, Chen E, Qian X. A narrative review on perioperative pain management strategies in enhanced recovery pathways-The past, present and future. J Clin Med 2021; 10:2568.
- Momose A, Yamaguchi S, Okada A, et al. Factors associated with long-term care certification in older adults: A cross-

sectional study based on a nationally representative survey in Japan. *BMC Geriatr* 2021; 21:374.

- Bell T, Franz CE, Kremen WS. Persistence of pain and cognitive impairment in older adults. J Am Geriatr Soc 2022; 70:449-458.
- Hooten WM, Townsend CO, Sletten CD. The triallelic serotonin transporter gene polymorphism is associated with depressive symptoms in adults

with chronic pain. J Pain Res 2017; 10:1071-1078.

- Brandl F, Weise B, Mulej Bratec S, et al. Common and specific large-scale brain changes in major depressive disorder, anxiety disorders, and chronic pain: A transdiagnostic multimodal metaanalysis of structural and functional MRI studies. *Neuropsychopharmacology* 2022; 47:1071-1080.
- Glare P, Aubrey KR, Myles PS. Transition

from acute to chronic pain after surgery. *Lancet* 2019; 393:1537-1546.

- Richebe P, Capdevila X, Rivat C. Persistent postsurgical pain: Pathophysiology and preventative pharmacologic considerations. Anesthesiology 2018; 129:590-607.
- Brinck EC, Tiippana E, Heesen M, et al. Perioperative intravenous ketamine for acute postoperative pain in adults. *Cochrane Database Syst Rev* 2018; 12:CD012033.
- Wang X, Lin C, Lan L, et al. Perioperative intravenous S-ketamine for acute postoperative pain in adults: A systematic review and meta-analysis.] Clin Anesth 2021; 68:110071.
- Chaparro LE, Smith SA, Moore RA, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. *Cochrane Database Syst Rev* 2013; 2013:CD008307.
- McNicol ED, Schumann R, Haroutounian S. A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain. Acta Anaesthesiol Scand 2014; 58:1199-1213.
- Carley ME, Chaparro LE, Choiniere M, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults: An updated systematic review and meta-analysis. *Anesthesiology* 2021; 135:304-325.
- Chumbley GM, Thompson L, Swatman JE, et al. Ketamine infusion for 96 hr after thoracotomy: Effects on acute and persistent pain. Eur J Pain 2019; 23:985-993.
- 15. Hu J, Liao Q, Zhang F, et al. Chronic postthoracotomy pain and perioperative ketamine infusion. J Pain Palliat Care Pharmacother 2014; 28:117-121.
- Tena B, Gomar C, Rios J. Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy. *Clin J Pain* 2014; 30:490-500.
- Suzuki M, Haraguti S, Sugimoto K, et al. Low-dose intravenous ketamine potentiates epidural analgesia after thoracotomy. *Anesthesiology* 2006; 105:111-119.
- Duale C, Sibaud F, Guastella V, et al. Perioperative ketamine does not prevent chronic pain after thoracotomy. *Eur J Pain* 2009; 13:497-505.
- Mendola C, Cammarota G, Netto R, et al. S(+)-ketamine for control of perioperative pain and prevention

of post thoracotomy pain syndrome: A randomized, double-blind study. *Minerva Anestesiol* 2012; 78:757-766.

- Aveline C, Roux AL, Hetet HL, et al. Pain and recovery after total knee arthroplasty: A 12-month follow-up after a prospective randomized study evaluating nefopam and ketamine for early rehabilitation. Clin J Pain 2014; 30:749-754.
- 21. Remerand F, Le Tendre C, Baud A, et al. The early and delayed analgesic effects of ketamine after total hip arthroplasty: A prospective, randomized, controlled, double-blind study. *Anesth Analg* 2009; 109:1963-1971.
- 22. Perrin SB, Purcell AN. Intraoperative ketamine may influence persistent pain following knee arthroplasty under combined general and spinal anaesthesia: A pilot study. Anaesth Intensive Care 2009; 37:248-253.
- 23. Nielsen RV, Fomsgaard JS, Siegel H, et al. Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: A randomized, blinded trial. Pain 2017; 158:463-470.
- 24. Czarnetzki C, Desmeules J, Tessitore E, et al. Perioperative intravenous low-dose ketamine for neuropathic pain after major lower back surgery: A randomized, placebo-controlled study. *Eur J Pain* 2020; 24:555-567.
- Hayes C, Armstrong-Brown A, Burstal R. Perioperative intravenous ketamine infusion for the prevention of persistent post-amputation pain: a randomized, controlled trial. Anaesth Intensive Care 2004; 32:330-338.
- 26. Zhao Z, Xu Q, Chen Y, et al. The effect of low-dose ketamine on postoperative quality of recovery in patients undergoing breast cancer surgery: A randomised, placebo-controlled trial. Int J Clin Pract 2021; 75:e15010.
- Kang C, Cho AR, Kim KH, et al. Effects of intraoperative low-dose ketamine on persistent postsurgical pain after breast cancer surgery: A prospective, randomized, controlled, double-blind study. Pain Physician 2020; 23:37-47.
- Lee J, Park HP, Jeong MH, et al. Efficacy of ketamine for postoperative pain following robotic thyroidectomy: A prospective randomised study. J Int Med Res 2018; 46:1109-1120.
- De Kock M, Lavand'homme P, Waterloos H. 'Balanced analgesia' in the perioperative period: Is there a place for ketamine? *Pain* 2001; 92:373-380.

- 30. Spreng UJ, Dahl V, Raeder J. Effects of perioperative S (+) ketamine infusion added to multimodal analgesia in patients undergoing ambulatory haemorrhoidectomy. Scand J Pain 2010; 1:100-105.
- Jendoubi A, Naceur IB, Bouzouita A, et al. A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth 2017; 11:177-184.
- Peyton PJ, Wu C, Jacobson T, et al. The effect of a perioperative ketamine infusion on the incidence of chronic postsurgical pain-A pilot study. Anaesth Intensive Care 2017; 45:459-465.
- 33. Bilgen S, Koner O, Ture H, et al. Effect of three different doses of ketamine prior to general anaesthesia on postoperative pain following caesarean delivery: A prospective randomized study. *Minerva Anestesiol* 2012; 78:442-449.
- Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth 2008; 101:77-86.
- 35. Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment of complex regional pain syndrome: A systemic review and meta-analysis. Curr Pain Headache Rep 2018; 22:12.
- Orhurhu V, Orhurhu MS, Bhatia A, et al. Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. *Anesth Analg* 2019; 129:241-254.
- Sheng J, Liu S, Wang Y, et al. The link between depression and chronic pain: Neural mechanisms in the brain. Neural Plast 2017; 2017:9724371.
- Humo M, Lu H, Yalcin I. The molecular neurobiology of chronic pain-induced depression. Cell Tissue Res 2019; 377:21-43.
- Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: A literature review. Arch Intern Med 2003; 163:2433-2445.
- 40. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatmentresistant depression: An international expert opinion on the available evidence and implementation. Am J Psychiatry 2021; 178:383-399.
- Zhou Y, Sun W, Zhang G, et al. Ketamine alleviates depressive symptoms in patients undergoing intracranial tumor resection: A randomized controlled trial. Anesth Analg 2021; 133:1588-1597.

- Fregoso G, Wang A, Tseng K, et al. Transition from acute to chronic pain: Evaluating risk for chronic postsurgical pain. Pain Physician 2019; 22:479-488.
- Mei WJ, Fei LH, Yan JH. Acute Post Surgical Pain may result in chronic post surgical pain: A systemic review

and meta analysis. *Pak J Med Sci* 2015; 45. 31:833-836.

- IsHak WW, Wen RY, Naghdechi L, et al. Pain and depression: A systematic review. Harv Rev Psychiatry 2018; 26:352-363.
- Tola YO, Chow KM, Liang W. Effects of non-pharmacological interventions on preoperative anxiety and postoperative pain in patients undergoing breast cancer surgery: A systematic review. J Clin Nurs 2021; 30:3369-3384.

	Experi	mental	c	Control	Favors Favors			Weight	Weight
Study	Events	Total	Events	Total	intervention control	RR	95%-Cl	(common)	(random)
Duale-2009	19	39	15	41	- <u>+</u>	1.33	[0.79; 2.23]	6.0%	6.9%
Remerand-2009	34	79	48	75		0.67	[0.50; 0.91]	20.1%	16.4%
Spreng-2010	2	39	4	38		0.49	[0.09; 2.51]	1.7%	0.8%
Mendola-2012	10	32	7	30		1.34	[0.59; 3.06]	2.9%	2.9%
Bilgen-2012	6	115	1	35		1.83	[0.23; 14.66]	0.6%	0.5%
Hu-2014	4	31	5	47		1.21	[0.35; 4.17]	1.6%	1.3%
Tena-2014	2	33	2	35		1.06	[0.16; 7.10]	0.8%	0.6%
Nielsen-2017	22	74	21	73	_ <u>+</u>	1.03	[0.62; 1.71]	8.6%	7.2%
Jendoubi-2017	13	20	15	20		0.87	[0.58; 1.30]	6.1%	10.3%
Lee-2018	7	32	5	32		1.40	[0.50; 3.95]	2.0%	1.9%
Chumbley-2019	17	35	14	35		1.21	[0.71; 2.06]	5.7%	6.6%
Zhao-2021	25	48	26	49	_ <u>+</u>	0.98	[0.67; 1.43]	10.5%	11.8%
Kang-2020	39	88	38	89		1.04	[0.74; 1.45]	15.4%	14.2%
Czarnetzki-2020	43	78	44	78	÷	0.98	[0.74; 1.29]	17.9%	18.6%
Common effect model		743		677	1	0.98	[0.86; 1.12]	100.0%	
Random effects model					4	0.97	[0.84; 1.12]		100.0%
Heterogeneity: /2 = 0%, t2 =	0.0087, p =	0.66							
					0.1 0.5 1 2 10				

Supplemental Fig. 1. *Secondary outcome-PONV*. PONV: Postoperative nausea and vomiting.

Study	Experi Events	mental Total	C Events	Control Total	Favors Favors intervention control	RR	95%-CI	Weight (common)	Weight (random)
								, , ,	, ,
Dekock-2001	0	38	0	18	!			0.0%	0.0%
Remerand-2009	8	79	11	75	<u>+</u>	0.69	[0.29; 1.62]	33.0%	21.8%
Spreng-2010	0	39	0	38	— i			0.0%	0.0%
Bilgen-2012	1	115	0	35		0.92	[0.04; 22.14]	2.2%	3.0%
Hu-2014	7	31	4	47		2.65	[0.85; 8.31]	9.3%	15.7%
Tena-2014	4	33	2	35		2.12	[0.42; 10.82]	5.7%	9.5%
Nielsen-2017	1	74	1	73		0.99	[0.06; 15.48]	2.9%	3.9%
Jendoubi-2017	0	20	0	20	!			0.0%	0.0%
Lee-2018	0	32	0	32				0.0%	0.0%
Chumbley-2019	13	35	2	35		6.50	[1.58; 26.71]	5.9%	11.8%
Zhao-2021	0	48	0	49	i			0.0%	0.0%
Kang-2020	2	88	2	89	<u></u>	1.01	[0.15; 7.02]	5.8%	7.2%
Czarnetzki-2020	18	76	12	76	- 1	1.50	[0.78; 2.90]	35.1%	27.1%
Common effect model		708		622	-	1.61	[1.09; 2.39]	100.0%	
Random effects model						1.60	[0.91; 2.84]		100.0%
Heterogeneity: $l^2 = 20\%$, $t^2 = 10\%$	= 0.1998, <i>p</i> :	= 0.27			0.1 0.5 1 2 10				

Supplemental Fig. 2. Secondary outcome-hallucinations.

Study	Favors intervention	Favors control	MD	95%-Cl	Weight (common)	Weight (random)
Remerand-2009	÷	1	-7.00	[-12.22; -1.78]	21.0%	15.7%
Perrin-2009		<u> </u>	-15.30	[-40.72; 10.12]	0.9%	9.8%
Bilgen-2012(0.25mg/kg)	;		8.00	[0.18; 15.82]	9.4%	15.2%
Bilgen-2012(0.5mg/kg)	1		8.00	[0.70; 15.30]	10.8%	15.3%
Bilgen-2012(1mg/kg)	ý -	*	4.00	[-2.11; 10.11]	15.4%	15.5%
Nielsen-2017	ì		-42.00	[-58.20; -25.80]	2.2%	12.7%
Jendoubi-2017	≡j.		-15.60	[-19.37; -11.83]	40.4%	15.9%
Common effect model	1		-6.59	[-8.99; -4.20]	100.0%	
Random effects model		-	-7.37	[-20.06; 5.33]		100.0%
Heterogeneity: $l^2 = 93\%$, $t^2 = 260.921$		0 20 40				

Supplemental Fig. 3. Secondary outcome-48 hours postoperative opioid consumption.

	Experi	mental		Control	Favors Favors			Weight	Weigh
Study	Events	Total	Events	Total	intervention control	RR	95%-Cl	(common)	(random
Surgery = Orthopaedic s	urgery				i				
Hayes-2004	4	15	4	16		1.07	[0.32; 3.52]	1.2%	1.49
Perrin-2009	3	5	2	7		- 2.10	[0.53; 8.29]	0.5%	1.1
Remerand-2009	6	72	21	70	!	0.28	[0.12; 0.65]	6.5%	2.7
Aveline-2014	2	24	6	23		0.32	[0.07; 1.42]	1.9%	0.9
Nielsen-2017	38	43	49	52	il.	0.94	[0.83; 1.07]	13.4%	17.6
Czarnetzki-2020	21	73	16	68	<u></u>	1.22	[0.70; 2.14]	5.0%	5.2
Common effect model	-	232		236		0.82	[0.68; 1.00]	28.4%	-
Random effects model		202		200		0.81	[0.47; 1.39]		28.9
Heterogeneity: $l^2 = 59\%$, $t^2 =$	0.2633, p	= 0.03			1 1		[0111, 1100]		2010
Surgery = Thoracotomy					i i i i i i i i i i i i i i i i i i i				
Suzuki-2006	7	22	14	22	<u> </u>	0.50	[0.25; 1.00]	4.2%	3.8
Duale-2009	16	34	24	35	<u>t</u>	0.69	[0.45; 1.05]	7.2%	7.7
Mendola-2012	11	31	8	30		1.33	[0.62; 2.84]	2.5%	3.2
Hu-2014	18	31	24	47		1.14	[0.75; 1.71]	5.8%	7.9
Tena-2014	9	33	17	35	<u></u> #	0.56	[0.29; 1.08]	5.0%	4.1
Pevton-2017	8	40	6	40		1.33	[0.51; 3.49]	1.8%	2.1
Chumbley-2019	10	33	8	34		1.29	[0.58; 2.86]	2.4%	3.0
Common effect model		224		243	4	0.87	[0.70; 1.09]	28.9%	
Random effects model					4	0.87	[0.64; 1.18]		31.8
Heterogeneity: I ² = 40%, t ² =	0.0624, p	= 0.13			i i				
Surgery = Abdominal su									
Dekock-2001	2	38	6	18		0.16	[0.04; 0.71]	2.5%	0.9
Spreng-2010	6	39	3	38	-il	- 1.95	[0.52; 7.24]	0.9%	1.2
Bilgen-2012	6	115	2	35	č	0.91	[0.19; 4.32]	0.9%	0.9
Jendoubi-2017	7	20	9	20		0.78	[0.36; 1.68]	2.7%	3.1
Peyton-2017	8	40	6	40		1.33	[0.51; 3.49]	1.8%	2.1
Common effect model		252		151		0.86	[0.54; 1.36]	8.9%	-
Random effects model	0.0270 0	0.10				0.85	[0.43; 1.66]		8.3
Heterogeneity: I ² = 45%, t ² =									
Surgery = Thyroid or bre	-	-			5 				
Peyton-2017	8	40	6	40		1.33	[0.51; 3.49]	1.8%	2.1
_ee-2018	9	25	10	24		0.86	[0.43; 1.75]	3.1%	3.6
Zhao-2021	27	42	23	44	_ <u>+</u> =	1.23	[0.86; 1.76]	6.8%	9.2
Kang-2020	58	84	73	84		0.79	[0.67; 0.94]	22.1%	16.2
Common effect model		191		192	7	0.92	[0.78; 1.07]	33.8%	-
Random effects model					,	0.96	[0.71; 1.29]		31.1
-leterogeneity: I ² = 45%, t ² =	0.0401, p	= 0.14			į				
Common effect model		899		822	4	0.87	[0.78; 0.97]	100.0%	-
Random effects model						0.89	[0.77; 1.04]		100.0
Heterogeneity: / ² = 41%, t ² =						10			
	(fixed effec	t): c ₃ ² = 0.	70, df = 3 ()	p = 0.87	0.1 0.5 1 2	10			
Test for subgroup differences	(1110.0.010.0								


tudy E	Events	ental Total		ontrol Total	Favors Favors intervention control	RR	95%-CI	Weight (common)	Weight (random)	
tervention = Maximum in						0.00	10.07-1.07	0.00	0.00	
ekock-2001 uzuki-2006	2	19 22	6 14	18 22	i	0.32	[0.07; 1.37] [0.25; 1.00]	0.6%	0.3%	
emerand-2009	6	72	21	70		0.28	[0.12; 0.65]	2.2%	0.8%	
endola-2012	11	31	8	30		1.33	[0.62; 2.84]	0.9%	1.0%	
u-2014	18	31	24	47	1	1.14	[0.75; 1.71]	2.0%	2.7%	
veline-2014	2	24	6	23	<u>_</u>	0.32	[0.07; 1.42]	0.6%	0.3%	
ee-2018	9	25	10	24		0.86	[0.43; 1.75]	1.1%	1.1%	
humbley-2019	10	33	8	34		1.29	[0.58; 2.86]	0.8%	0.9%	
ang-2020	58	84	73	84	d	0.79	[0.67; 0.94]	7.6%	6.4%	
ommon effect model		341		352	4	0.76	[0.65; 0.89]	17.4%		
andom effects model eterogeneity: $l^2 = 52\%$, $t^2 = 0$.					-	0.75	[0.54; 1.05]		14.7%	
nerogeneity. / = 52%, t = 0.	.1291, p =	0.03								
tervention = Infusion rate ekock-2001					ć	0.07	[0.00; 1.21]	0.72		
екоск-2001 ayes-2004	0 4	19 15	6 4	18 16		0.07		0.7%	0.1%	
uale-2009	16	34	24	35	j.	0.69	[0.32; 3.52] [0.45; 1.05]	2.5%	2.6%	
errin-2009	3	5	2	7		2.10	[0.53; 8.29]	0.2%	0.3%	
preng-2010	6	39	3	38	i i	1.95	[0.52; 7.24]	0.3%	0.4%	
na-2014	9	33	17	35		0.56	[0.29; 1.08]	1.7%	1.3%	
elsen-2017	38	43	49	52	- 4	0.94	[0.83; 1.07]	4.6%	7.2%	
ndoubi-2017	7	20	9	20		0.78	[0.36; 1.68]	0.9%	1.0%	
yton-2017	8	40	6	40		1.33	[0.51; 3.49]	0.6%	0.6%	
ao-2021	27	42	23	44	9 <u>-</u> -	1.23	[0.86; 1.76]	2.4%	3.2%	
zarnetzki-2020	21	73	16	68	<u>r</u>	1.22	[0.70; 2.14]	1.7%	1.7%	
ommon effect model		363		373	4	0.94	[0.80; 1.09]	16.1%		
indom effects model					*	0.95	[0.81; 1.11]		18.7%	
terogeneity: $l^2 = 28\%$, $t^2 = 0$.	.0080, p =	0.17			ģ					
ervention = During surg	pory				5					
kock-2001	2	38	6	18		0.16	[0.04; 0.71]	0.9%	0.3%	
rrin-2009	3	5	2	7		2.10	[0.53; 8.29]	0.2%	0.3%	
reng-2010	6	39	3	38	_ <u>(</u>	1.95	[0.52; 7.24]	0.3%	0.4%	
elsen-2017	38	43	49	52	Q	0.94	[0.83; 1.07]	4.6%	7.2%	
e-2018	9	25	10	24		0.86	[0.43; 1.75]	1.1%	1.1%	
ao-2021	27	42	23	44	ém-	1.23	[0.86; 1.76]	2.4%	3.2%	
ng-2020	58	84	73	84		0.79	[0.67; 0.94]	7.6%	6.4%	
arnetzki-2020	21	73	16	68		1.22	[0.70; 2.14]	1.7%	1.7%	
mmon effect model		349		335	1	0.93	[0.82; 1.05]	18.8%		
ndom effects model					đ	0.94	[0.79; 1.12]		20.5%	
terogeneity: $l^2 = 52\%$, $t^2 = 0$.	.0181, p =	0.04								
ervention = Within 24 ho	ours				e					
ale-2009	16	34	24	35		0.69	[0.45; 1.05]	2.5%	2.6%	
merand-2009	6	72	21	70		0.28	[0.12; 0.65]	2.2%	0.8%	
ndoubi-2017	7	20	9	20		0.78	[0.36; 1.68]	0.9%	1.0%	
yton-2017	8	40	6	40		1.33	[0.51; 3.49]	0.6%	0.6%	
mmon effect model		166		165	•	0.62	[0.45; 0.86]	6.3%		Supplemental Fig. 5. Subgroup
indom effects model terogeneity: $l^2 = 52\%$, $t^2 = 0$.	4500 -	0.40			-	0.66	[0.39; 1.11]		5.0%	
terogeneity: /* = 52%, 1* = 0.	,1508, p =	0.10			2					infusion strategy.
tervention = More than 2	24 hours				i i					
iyes-2004	4	15	4	16		1.07		0.4%	0.4%	
izuki-2006	7	22	14	22		0.50	[0.25; 1.00]	1.5%	1.2%	
endola-2012 I-2014	11 18	31 31	8 24	30 47	d_	1.33	[0.62; 2.84]	0.9%	1.0%	
na-2014	9	33	17	35	il	1.14 0.56	[0.75; 1.71] [0.29; 1.08]	1.7%	1.3%	
eline-2014	2	24	6	23		0.38	[0.29, 1.08]	0.6%	0.3%	
umbley-2019	10	33	8	34	1	1.29	[0.58; 2.86]	0.8%	0.9%	
ommon effect model	10	189	0	207	1	0.86	[0.66; 1.12]	7.9%		
indom effects model		100		2.07		0.86	[0.60; 1.23]		7.8%	
terogeneity: $l^2 = 39\%$, $t^2 = 0$.	.0869, p =	0.13								
ervention = Bolus dosag	ae less th	an 0.5	ma/ka		í					
kock-2001	2 go 1055 ti	19	6 119789	18	<u> </u>	0.32	[0.07; 1.37]	0.6%	0.3%	
zuki-2006	7	22	14	22		0.50	[0.25; 1.00]	1.5%	1.2%	
reng-2010	6	39	3	38		1.95	[0.52; 7.24]	0.3%	0.4%	
ndola-2012	11	31	8	30	- 	1.33	[0.62; 2.84]	0.9%	1.0%	
eline-2014	2	24	6	23		0.32		0.6%	0.3%	
ndoubi-2017	7	20	9	20		0.78	[0.36; 1.68]	0.9%	1.0%	
e-2018	9	25	10	24		0.86	[0.43; 1.75]	1.1%	1.1%	
umbley-2019	10	33	8	34		1.29	[0.58; 2.86]	0.8%	0.9%	
mmon effect model ndom effects model		213		209	1	0.83	[0.61; 1.12] [0.59; 1.18]	6.8%	6.1%	
terogeneity: $l^2 = 27\%$, $t^2 = 0$.	.0469, p =	0.21			i	0.00	[0.00, 1.10]		0.170	
ervention = Bolus dosag					- i	0.07	10.00 1.00	0.75		
kock-2001	0	19	6	18	i	0.07	[0.00; 1.21]	0.7%	0.1%	
yes-2004	4	15 34	4 24	16 35	j.	1.07	[0.32; 3.52]	0.4%	0.4%	
ale-2009	16 6	34 72		35 70		0.69	[0.45; 1.05]	2.5%	2.6%	
merand-2009 rrin-2009	6 3	72	21 2	70		0.28 2.10	[0.12; 0.65] [0.53; 8.29]	2.2%	0.8%	
mn-2009 I-2014	18	31	24	47	1	1.14	[0.53; 8.29]	2.0%	2.7%	
na-2014	18	31	17	35		0.56	[0.29; 1.08]	2.0%	1.3%	
elsen-2017	38	43	49	52	- 0	0.94	[0.83; 1.07]	4.6%	7.2%	
yton-2017	8	40	49	40	<u> </u>	1.33	[0.63; 1.07]	0.6%	0.6%	
ao-2021	27	42	23	44	4	1.23	[0.86; 1.76]	2.4%	3.2%	
ng-2020	58	84	73	84	d	0.79	[0.67; 0.94]	7.6%	6.4%	
arnetzki-2020	21	73	16	68	-4=	1.22	[0.70; 2.14]	1.7%	1.7%	
ommon effect model		491		516	à	0.85	[0.76; 0.95]	26.7%		
indom effects model					1	0.89	[0.74; 1.07]		27.2%	
terogeneity: $l^2 = 54\%$, $t^2 = 0$.	.0380, p =	0.01			ğ					
		2112		2157		0.85	[0.80; 0.90]	100.0%	-	
ommon effect model					1					
ommon effect model andom effects model					•	0.88	[0.81; 0.95]	-	100.0%	
	.0194, p <				0.01 0.1 1 10 100	0.88	[0.81; 0.95]	-	100.0%	


Study	Experi Events	mental Total	C Events	Control Total	Favors intervention	Favors control	RR	95%-Cl	Weight (common)	Weig (randoi
Endpoint = Less than 3	months				1	1				
Dekock-2001	3	38	5	19		l.	0.30	[0.08; 1.12]	1.1%	0.5
Suzuki-2006	12	24	19	24			0.63	[0.40; 0.99]	3.0%	3.4
Duale-2009	23	36	23	37	_		1.03	[0.72; 1.46]	3.6%	4.8
Mendola-2012	25	32		30		Ē.				6.1
			22			Ē.	1.07	[0.80; 1.41]	3.6%	
Bilgen-2012	14	115	3	35			1.42	[0.43; 4.66]	0.7%	0.0
Hu-2014	27	31	34	47		*	1.20	[0.96; 1.50]	4.3%	7.
Chumbley-2019	21	34	17	35	1	* -	1.27	[0.83; 1.96]	2.7%	3.
(ang-2020	71	84	79	84		1	0.90	[0.81; 1.00]	12.5%	10.
Common effect model		394		311			0.97	[0.88; 1.08]	31.5%	
andom effects model							0.99	[0.85; 1.16]		37.
eterogeneity: $I^2 = 52\%$, $t^2 =$	= 0.0173, p	= 0.04								
ndpoint = 3 months										
Suzuki-2006	7	22	14	22			0.50	[0.25; 1.00]	2.2%	1.
Spreng-2010	6	39	3	38	_		1.95	[0.52; 7.24]	0.5%	0.
Aendola-2012	11	31	8	30			1.33		1.3%	1.
						-		[0.62; 2.84]		
ena-2014	9	33	17	35		1	0.56	[0.29; 1.08]	2.6%	1.
lendoubi-2017	7	20	9	20			0.78	[0.36; 1.68]	1.4%	1.
.ee-2018	9	25	10	24		-	0.86	[0.43; 1.75]	1.6%	1.
Chumbley-2019	10	33	8	34	_	*	1.29	[0.58; 2.86]	1.3%	1.
2hao-2021	27	42	23	44	1	.	1.23	[0.86; 1.76]	3.6%	4.
(ang-2020	58	84	73	84	E		0.79	[0.67; 0.94]	11.6%	9.
Common effect model		329		331			0.88	[0.76; 1.02]	26.1%	
Random effects model deterogeneity: $I^2 = 36\%$, $t^2 = 36\%$	= 0.0374, p	= 0.13					0.89	[0.71; 1.12]	-	23.
Endpoint = 3-6 months										
Dekock-2001	2	38	6	18			0.16	[0.04; 0.71]	1.3%	0.
Hayes-2004	4	15	4	16			1.07	[0.32; 3.52]	0.6%	0.
Suzuki-2006	6	22	11	22			0.55	[0.25; 1.21]	1.7%	1.
Duale-2009	16	34	24	35						
							0.69	[0.45; 1.05]	3.8%	3.
Remerand-2009	6	72	21	70			0.28	[0.12; 0.65]	3.4%	1.
Perrin-2009	3	5	2	7			2.10	[0.53; 8.29]	0.3%	0.
Mendola-2012	9	29	4	28	-		2.17	[0.75; 6.25]	0.6%	0.
Bilgen-2012	6	115	2	35		<u> </u>	0.91	[0.19; 4.32]	0.5%	0.
Hu-2014	18	31	24	47	-		1.14	[0.75; 1.71]	3.0%	3.
Tena-2014	5	33	11	35		-	0.48	[0.19; 1.24]	1.7%	1.
Aveline-2014	2	24	6	23			0.32	[0.07; 1.42]	1.0%	0.
Nielsen-2017	38	43	49	52		l,	0.94	[0.83; 1.07]	7.0%	10.
Peyton-2017	8	40	6	40		í	1.33	[0.51; 3.49]	1.0%	1.
,	-		-							
Chumbley-2019	5	31	6	32			0.86	[0.29; 2.53]	0.9%	0.
(ang-2020	46	82	55	81			0.83	[0.65; 1.05]	8.8%	7.
Czarnetzki-2020	21	73	16	68		-	1.22	[0.70; 2.14]	2.6%	2.
Common effect model		687		609			0.82	[0.72; 0.94]	38.3%	
Random effects model Heterogeneity: I ² = 45%, t ² =	= 0.0337. n	= 0.03					0.85	[0.70; 1.02]		35.
ndpoint = 1 year ekock-2001	0	37	3	17			0.07	10.00 1.001	0.8%	0
				17	-	[0.07	[0.00; 1.22]		0.
Bilgen-2012	3	115	0	35			2.15	[0.11; 40.67]	0.1%	0.
Aveline-2014	2	24	4	23			0.48	[0.10; 2.37]	0.6%	0.
Chumbley-2019	3	28	4	28		<u> </u>	0.75	[0.18; 3.05]	0.6%	0.
Zarnetzki-2020	19	72	12	67	4	*	1.47	[0.78; 2.80]	2.0%	2.
Common effect model		276		170	-		0.97	[0.59; 1.59]	4.1%	
Random effects model							0.88	[0.41; 1.90]		3.
leterogeneity: /2 = 32%, t2 =	= 0.2126, p	= 0.21								
Common effect model		1686		1421			0.89	[0.83; 0.96]	100.0%	
							0.92	[0.83; 1.01]		100
Random effects model										
Random effects model leterogeneity: / ² = 41%, t ² =	= 0.0206, <i>p</i> ·	< 0.01								
			11, df = 3 (µ	9 = 0.25)	0.01 0.1	1 10 100				


	Experi	mental	0	Control	Favors	Favors			Weight	Weigl
Study	Events	Total	Events	Total	intervention		RR	95%-CI	(common)	(randon
Accessment = NRS/VAS	}				i	I				
Suzuki-2006	7	22	14	22			0.50	[0.25; 1.00]	3.9%	2.9
Mendola-2012	11	31	8	30	-	-	1.33	[0.62; 2.84]	2.3%	2.4
Tena-2014	9	33	17	35	(ł	0.56	[0.29; 1.08]	4.6%	3.2
Hu-2014	18	31	24	47	÷		1.14	[0.75; 1.71]	5.3%	6.8
Nielsen-2017	38	43	49	52			0.94	[0.83; 1.07]	12.4%	20.6
Peyton-2017	8	40	6	40			1.33	[0.51; 3.49]	1.7%	1.6
_ee-2018	9	25	10	24	i	<u> </u>	0.86	[0.43; 1.75]	2.9%	2.8
Chumbley-2019	10	33	8	34			1.29	[0.58; 2.86]	2.2%	2.2
(ang-2020	58	84	73	84			0.79	[0.67; 0.94]	20.4%	18.0
Common effect model		342		368			0.88	[0.78; 0.99]	55.7%	
andom effects model							0.89	[0.78; 1.01]		60.4
leterogeneity: $l^2 = 27\%$, t ²	= 0.0071, p	= 0.20			([0110, 1101]		
ccessment = DN4					r i					
veline-2014	2	24	6	23		F	0.32	[0.07; 1.42]	1.7%	0.7
endoubi-2017	7	20	9	20			0.78	[0.36; 1.68]	2.5%	2.4
vielsen-2017	20	43	22	52			1.10	[0.70; 1.73]	5.6%	5.9
Zhao-2021	27	42	23	44	l l	-	1.23	[0.86; 1.76]	6.3%	8.
Zarnetzki-2020	21	73	16	68	<u>+</u>	-	1.22	[0.70; 2.14]	4.6%	4.
(ang-2020	3	84	5	84	i		0.60	[0.15; 2.43]	1.4%	0.8
Common effect model		286		291	i		1.03	[0.81; 1.31]	22.1%	
Random effects model							1.08	[0.86; 1.37]		21.9
Heterogeneity: $l^2 = 0\%$, $t^2 =$	< 0.0001, p	= 0.46						[0.00, 1.01]		
Accessment = DIY					l.					
Dekock-2001	2	38	6	18	<u>`</u>		0.16	[0.04; 0.71]	2.3%	0.7
layes-2004	4	15	4	16	1		1.07	[0.32; 3.52]	1.1%	1.0
Remerand-2009	6	72	21	70	•		0.28	[0.12; 0.65]	6.0%	2.0
ilgen-2012	6	115	2	35			0.91	[0.19; 4.32]	0.9%	0.0
common effect model		240		139			0.39	[0.22; 0.68]	10.2%	
andom effects model							0.44	[0.19; 1.04]		4.3
leterogeneity: $l^2 = 49\%$, t ² :	= 0.3663, p	= 0.12								
Accessment = NPSI					Ĺ					
uale-2009	16	34	24	35	- 	ł	0.69	[0.45; 1.05]	6.6%	6.5
lendola-2012	18	31	19	30	-)	-	0.92	[0.61; 1.37]	5.4%	6.9
common effect model		65		65	-	ł	0.79	[0.59; 1.06]	12.0%	
Random effects model						ł	0.80	[0.60; 1.07]		13.4
Heterogeneity: $I^2 = 0\%$, $t^2 =$	0, <i>p</i> = 0.33				ć					
common effect model		933		863	-		0.85	[0.77; 0.95]	100.0%	
Random effects model							0.88	[0.78; 1.00]		100.0
leterogeneity: I ² = 38%, t ² :	= 0.0151, p	= 0.04								
est for subgroup differences	Were de Mara	$r = 2^2 - 10^2$	62 df - 2	(0 - 0 01)	0.1 0.5	1 2 10				

Supplemental Fig. 7. Subgroup-assessment scale. NRS-11: Numeric Rating Scale. VAS: Visual Analog Scale. DN4: Douleur Neuropathique 4 questionnaire. DIY: "design it yourself", means self-designed scale. NPSI: Neuropathic Pain Symptoms Inventory.

Study	Risk Ratio	RR	95%-CI
Omitting Dekock-2001		0.89	[0.77; 1.04]
Omitting Hayes-2004		0.87	[0.74; 1.03]
Omitting Suzuki-2006		0.90	[0.78; 1.04]
Omitting Duale-2009		0.90	[0.76; 1.06]
Omitting Remerand-2009		0.91	[0.79; 1.03]
Omitting Perrin-2009		0.87	[0.74; 1.02]
Omitting Spreng-2010		0.87	[0.74; 1.02]
Omitting Mendola-2012		0.86	[0.73; 1.02]
Omitting Bilgen-2012		0.88	[0.75; 1.03]
Omitting Hu-2014		0.86	[0.72; 1.01]
Omitting Tena-2014		0.90	[0.77; 1.05]
Omitting Aveline-2014		0.89	[0.76; 1.04]
Omitting Nielsen-2017		0.86	[0.71; 1.05]
Omitting Jendoubi-2017		0.88	[0.74; 1.04]
Omitting Peyton-2017		0.87	[0.74; 1.02]
Omitting Lee-2018		0.88	[0.74; 1.04]
Omitting Chumbley-2019		0.86	[0.73; 1.02]
Omitting Zhao-2021		0.85	[0.74; 0.98]
Omitting Kang-2020		0.88	[0.73; 1.07]
Omitting Czarnetzki-2020		0.86	[0.73; 1.01]
Random effects model	:	0.88	[0.75; 1.03]
		-	
	0.8 1	1.25	
Supplemental Fig. 8. Sensitivity an	alysis.		







Supplemental Table	. The incidence of	ADRs based of	n the included studies.
--------------------	--------------------	---------------	-------------------------

ADRs	Events/Total	Incidence(%)	Study ID
PONV	243/743	32.7	Duale 2009, Remerand 2009, Spreng 2010, Mendola 2012, Bligen 2012, Hu 2014, Tena 2014, Nielsen 2017, Jendoubi 2017, Lee 2018, Chumbley 2019, Zhou 2021, Kang 2020, Czarnetzki 2020
Hallucinations	54/708	7.6	Dekock 2001, Remerand 2009, Spreng 2010, Bligen 2012, Hu 2014, Tena 2014, Nielsen 2017, Jendoubi 2017, Lee 2018, Chumbley 2019, Zhou 2021, Kang 2020, Czarnetzki 2020
Nightmares	23/359	6.4	Dekock 2001, Remerand 2009, Nielsen 2017, Lee 2018, Zhou 2021, Kang 2020
Sedation or Drowsiness	49/298	16.4	Duale 2009, Tena 2014, Nielsen 2017, Chumbley 2019, Zhou 2021, Czarnetzki 2020
Trouble with vision	27/298	9.1	Remerand 2009, Spreng 2010, Bligen 2012, Tena 2014, Lee 2018
Hemodynamic side effects	13/104	12.5	Duale 2009,Mendola 2012, Tena 2014
Neurologic side effects	5/113	4.4	Mendola 2012, Tena 2014, Zhou 2021
Dizziness	22/74	29.7	Duale 2009, Chumbley 2019

Abbreviations: ADRs, adverse drug reactions; PONV, postoperative nausea and vomiting.